Tech Company Financing Transactions
Sitryx Therapeutics Funding Round
On 9/27/2023, Sitryx Therapeutics raised $39 million in Series A funding from Eli Lilly and Company, GlaxoSmithKline and Longwood Fund.
Transaction Overview
Company Name
Announced On
9/27/2023
Transaction Type
Venture Equity
Amount
$39,000,000
Round
Series A
Investors
Proceeds Purpose
The company will use the funds to progress development of disease-modifying therapeutics for chronic autoimmune and inflammatory disease.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
101 Bellhouse Building Magdalen Centre The Oxford Science Pa
Oxford, OX4 4GA
UK
Oxford, OX4 4GA
UK
Phone
Undisclosed
Website
Email Address
Overview
Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Neil Weir
Chief Financial Officer
Jonathan Senior
Chief Marketing Officer
Ravi Ravo
Chief Scientific Officer
Iain Kilty
Browse more venture capital transactions:
Prev: 9/27/2023: Lucid Scientific venture capital transaction
Next: 9/27/2023: Neara venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs